Effect of gonadotropin-releasing hormone agonist on the bone mineral density of patients with endometriosis

Tsuguo Uemura, Uemura T, T Uemura, Mohri J, J Mohri, Jun Mohri, Hisabumi Osada, H. Osada, Osada H, Suzuki N, N Suzuki, Naoyuki Suzuki, N. KATAGIRI, Katagiri N, Minaguchi H, H. Minaguchi
Fertility and sterility · 1994 · vol. 62(2) , pp. 246–250 · doi:10.1016/s0015-0282(16)56873-3 · PMID:8034067 · W2411341339
Non-randomised trial OA: closed CC0 ⤵ 11 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study investigated the impact of gonadotropin-releasing hormone agonist treatment on bone mineral density in patients diagnosed with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To examine changes in bone mineral density (BMD) of patients treated with GnRH agonist (GnRH-a) by dual-energy X-ray absorptiometry and to understand factors related to bone loss. DESIGN: Prospective controlled trial examining BMD during and after GnRH-a therapy every 24 weeks for 18 months in patients with endometriosis compared with nontreated controls. SETTING: Outpatients clinic at a university hospital and its affiliated outpatient clinic. PATIENTS: Twenty-two patients with endometriosis as GnRH-a-treated group, 12 healthy women with normal menstrual cycle, and 7 patients with mild endometriosis as control group. INTERVENTIONS: Patients were treated with a GnRH-a (buserelin acetate) at 900 micrograms/d by nasal spray for 24 weeks. RESULTS: The significance of differences in change-rates at all measured points in both groups was assessed by analysis of variance. The interaction between treatment and period was significant, and only week 24 of the GnRH-a-treated group was significantly lower compared with baseline. The reduction rate of BMD was high in patients 33 years of age or younger compared with those who were 34 years of age or older. According to a multiple-regression model, the most important factor related to bone loss was the post-treatment serum levels of E2. CONCLUSION: At the end of treatment, BMD was significantly lower than that of the control group, and the reduction rate was 3.4%. A factor related to bone loss was degree of ovarian suppression.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Bone Density Buserelin Endometriosis Endometriosis Adult Adult Bone and Bones Bone and Bones Bone and Bones Bone Density Bone Density Buserelin Buserelin Endometriosis Endometriosis Female Female Gonadal Steroid Hormones Gonadal Steroid Hormones Gonadal Steroid Hormones

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (15)

Cited by (12)

Source provenance

europepmc
last seen: 2026-10-12T06:17:10.165071+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:59:14.651011+00:00
unpaywall
last seen: 2026-09-18T06:25:56.777850+00:00
License: CC0 · commercial use OK